EUVIMEDEUVIMED entdecken
Crossref

Changes In Biologic Drug Revenues After Administrative Patent Challenges

Adam J N Raymakers, Victor L Van de Wiele, Aaron S Kesselheim, S Sean Tu

Health Affairs · 01.03.2025 · 44 (3) · 274-279

DOI: 10.1377/hlthaff.2024.00504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs, erschienen am 01.03.2025. Verfasst von Adam J N Raymakers und 3 weiteren Autor:innen. Beteiligte Einrichtung: Adam J. N. Raymakers, Harvard University and Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Patents as Topic, Biosimilar Pharmaceuticals, Drug Industry, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: National Institute for Health Care Management, Arnold Ventures and the Commonwealth Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2012, the America Invents Act created a new administrative pathway called inter partes review to allow challenges to patents as being improperly granted, including patents associated with brand-name prescription drugs that block timely competition. Manufacturers of expensive biologic drugs often obtain large numbers of patents on drugs approved by the Food and Drug Administration, which can make it harder for other manufacturers to market their own biosimilar versions of the products. We found that biologic drugs were associated with forty-three administrative patent challenges via inter partes review during the period 2012-21 that resulted in final written decisions. Biosimilar manufacturers used this pathway in twenty cases to invalidate fourteen patents, typically directed to new methods of treatment. By contrast, biologic manufacturers selling competing brand-name products in the same drug class used this pathway to invalidate seventeen patents in the twenty-three challenges they brought, typically directed to active drug ingredients. After patent invalidation by biosimilar firms, revenues for the originator products tended to decrease, a signal of more effective competition making drugs more accessible for the benefit of patients and payers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patents as TopicBiosimilar PharmaceuticalsDrug IndustryBiological ProductsUnited StatesHumansUnited States Food and Drug AdministrationEconomic CompetitionDrug Approval

Substanzen

Biosimilar PharmaceuticalsBiological Products

Autor:innen und Institutionen

  • Adam J. N. Raymakers, Harvard University and Brigham and Women's Hospital, Boston, Massachusetts.
  • Victor L. Van de Wiele, Harvard University and Brigham and Women's Hospital.
  • Aaron S. Kesselheim, Harvard University and Brigham and Women's Hospital.
  • S. Sean Tu (shinetu@gmail.com), West Virginia University, Morgantown, West Virginia.

Förderung

  • National Institute for Health Care Management
  • Arnold Ventures and the Commonwealth Fund

Zitieren

APA

Raymakers, A. J. N., Van de Wiele, V. L., Kesselheim, A. S., & Tu, S. S. (2025). Changes In Biologic Drug Revenues After Administrative Patent Challenges. Health Affairs, 44(3), 274-279. https://doi.org/10.1377/hlthaff.2024.00504

Vancouver

Raymakers AJN, Van de Wiele VL, Kesselheim AS, Tu SS. Changes In Biologic Drug Revenues After Administrative Patent Challenges. Health Affairs. 2025;44(3):274-279. doi:10.1377/hlthaff.2024.00504

BibTeX
@article{Raymakers2025,
  author = {Raymakers, Adam J N and Van de Wiele, Victor L and Kesselheim, Aaron S and Tu, S Sean},
  title = {Changes In Biologic Drug Revenues After Administrative Patent Challenges},
  journal = {Health Affairs},
  year = {2025},
  volume = {44},
  number = {3},
  pages = {274--279},
  doi = {10.1377/hlthaff.2024.00504}
}
Kostenlos starten →